Drugmakers point to US expansion plans amid Trump’s 100% drug tariff
The US will impose a 100% tariff on certain pharma products entering the country, the latest move by the Trump…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
BMS expands DTC offering with Sotyktu addition
Bristol Myers Squibb (BMS) has expanded its direct-to-consumer (DTC) offerings to include its autoimmune drug, Sotyktu (deucravacitinib). The medication, which…
-
UniQure stock surges 247% after mid-stage Huntington’s win
A Huntington’s gene therapy by UniQure has made waves after slowing disease progression by 75% in a mid-stage trial. During…
-
Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles
The US Food and Drug Administration (FDA) has rejected Biogen’s high-dose Spinraza (nusinersen) for the treatment of spinal muscular atrophy…
-
FDA actions Tylenol label change after Trump’s autism claim
Following US President Donald Trump’s claims that Tylenol (acetaminophen) use in pregnancy can cause autism, the US Food and Drug…
-
MSD wins SC Keytruda approval, but analysts sceptical on impact
MSD has secured approval from the US Food and Drug Administration (FDA) for its subcutaneous (SC) formulation of best-selling cancer…
-
MSD calls off £1bn UK expansion amid government-big pharma tensions
Merck & Co (MSD) has ditched plans for its £1bn R&D centre in London, UK, while ceasing drug discovery and…
-
Capricor refutes FDA’s DMD deramiocel rejection in public statement
Capricor Therapeutics has publicised a statement addressing the US Food and Drug Administration’s (FDA) decision to reject its Duchenne muscular…
-
Novartis snaps up promising ASCVD asset with Tourmaline acquisition
Swiss pharma giant Novartis has agreed to acquire clinical-stage biopharmaceutical company Tourmaline Bio for $1.4bn. Through this deal, Novartis will…
-
WHO adds GLP-1RAs to essential medicines list
The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and…